

IN THE CLAIMS:

The following amendment assumes that the Supplemental Amendment and Request for Reconsideration of January 14, 1997 was entered.

Please cancel claims 31 and 32 without prejudice or disclaimer. Please amend the claims, as follows:

D1
21. (Twice Amended) An isolated keratinocyte growth factor (KGF) polypeptide with preferential mitogenic activity on cells of epithelial origin, ~~said~~ polypeptide comprising amino acids 65-156 and 162-189 of Figure 7[, or a conservative amino acid substitution thereof].

D2
39. (Amended) A pharmaceutical composition comprising the polypeptide or portion thereof according to any one of claims 13, 14, 21, 23, 24, 28, 31, [32, or] 33-38 or 40 and a pharmaceutically acceptable carrier.

*out
e'*
40. (Amended) The polypeptide of claim [32] 13, [wherein peptide B comprises amino acids 65 through 194 of Figure 7] further comprising Met at the amino terminus.

REMARKS

With the entry of the amendment of January 14, 1997, claims 13, 14, 21, 23, 24, 29 and 31-40 became active in this case. Applicants herewith cancel claims 31 and 32 without prejudice or disclaimer and amend claims 21, 39 and 40. With the entry of the above amendment, claims 13, 14, 21, 23, 24, 29, and 33-40 will be pending in this application. A copy of the pending claims is attached for the Examiner's convenience (Appendix A).

Serial No. 08/477,983


Applicants also point out several minor mistakes that were made in the amendment filed January 14, 1997. Namely, applicants stated at page 5 of the amendment: "At page 39, line 20, delete "II-1" and insert --3--". This should have read "At page 39, line 17..." The second substitute specification contains the correctly amended text. Applicants also said "At page 39, line 24, after "." insert Table 3 from drawing sheet 9/16 (page 61)." Applicants should have said "At page 39, after line 21,...." The second substitute specification contains the correctly amended text. At page 6, of the amendment, applicants stated : "At page 44, line 6, delete "FGF-5". This should have read, "At page 45, line 6..." The second substitute specification contains the correctly amended text.

CONCLUSION

Applicants respectfully assert that claims 13, 14, 21, 23, 24, 29 and 33-40 meet all of the statutory requirements of patentability and therefore are in condition for allowance. Examiner Saoud is invited to contact the undersigned for any matter in furtherance of the prosecution of this case.

Respectfully submitted,

March 12, 1997
Date


Patricia D. Granados
Reg. No. 33,683

FOLEY & LARDNER
Suite 500
3000 K Street, N.W.
Washington, DC 20007-5109
(202) 672-5477

The Commissioner is hereby authorized to
charge any deficiency or credit any over-
payment to Deposit Account No. 19-0741